HDAC inhibition: A novel therapeutic target for pulmonary hypertension by reducing right ventricular hypertrophy through diverse pathological mechanisms

International Journal of Cardiology

Volumn 196, Issue , 2015, Pages 125-126

  Huang, Yi Yuan ^a   Fang, Zhen Fei ^a   Hu, Xin Qu ^a   Zhou, Sheng Hua ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Histone deacetylases(HDACs); Pulmonary hypertension; Right ventricular hypertrophy

Indexed keywords

CASPASE; HISTONE DEACETYLASE; HISTONE DEACETYLASE INHIBITOR;

ACETYLATION; CARDIAC REMODELING; DISEASE ASSOCIATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEART AFTERLOAD; HEART FUNCTION; HEART MUSCLE ISCHEMIA; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; LETTER; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN TARGETING; PULMONARY HYPERTENSION; REPERFUSION INJURY; DRUG DELIVERY SYSTEM; DRUG EFFECTS; HEART VENTRICLE REMODELING; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY;

DRUG DELIVERY SYSTEMS; HISTONE DEACETYLASE INHIBITORS; HUMANS; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; VENTRICULAR REMODELING;

EID: 84937397341     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2015.05.170     Document Type: Article

References (13)

1. J. Wang, X. Hu, and H. Jiang HDAC inhibition: a novel therapeutic target for attenuating myocardial ischemia and reperfusion injury by reversing cardiac remodeling Int. J. Cardiol. 190 2015 126 127
2. E.W. Bush, and T.A. McKinsey Protein acetylation in the cardiorenal axis: the promise of histone deacetylase inhibitors Circ. Res. 106 2010 272 284
3. Y.H. Kao, J.P. Liou, C.C. Chung, G.S. Lien, C.C. Kuo, S.A. Chen, and et al. Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure Int. J. Cardiol. 168 2013 4178 4183
4. S. Rich, J. Pogoriler, A.N. Husain, P.T. Toth, M. Gomberg-Maitland, and S.L. Archer Long-term effects of epoprostenol on the pulmonary vasculature in idiopathic pulmonary arterial hypertension Chest 138 2010 1234 1239
5. M.C. van de Veerdonk, T. Kind, J.T. Marcus, G.J. Mauritz, M.W. Heymans, H.J. Bogaard, and et al. Progressive right ventricular dysfunction in patients with pulmonary arterial hypertension responding to therapy J. Am. Coll. Cardiol. 58 2011 2511 2519
6. J.J. Ryan, and S.L. Archer The right ventricle in pulmonary arterial hypertension: disorders of metabolism, angiogenesis and adrenergic signaling in right ventricular failure Circ. Res. 115 2014 176 188
7. M. Xie, Y. Kong, W. Tan, H. May, P.K. Battiprolu, Z. Pedrozo, and et al. Histone deacetylase inhibition blunts ischemia/reperfusion injury by inducing cardiomyocyte autophagy Circulation 129 2014 1139 1151
8. T.A. McKinsey Therapeutic potential for HDAC inhibitors in the heart Annu. Rev. Pharmacol. Toxicol. 52 2012 303 319
9. Y.K. Cho, G.H. Eom, H.J. Kee, H.S. Kim, W.Y. Choi, K.I. Nam, and et al. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats Circ. J. 74 2010 760 770
10. L. Zhao, C.N. Chen, N. Hajji, E. Oliver, E. Cotroneo, J. Wharton, and et al. Histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid Circulation 126 2012 455 467
11. M.A. Cavasin, K. Demos-Davies, T.R. Horn, L.A. Walker, D.D. Lemon, N. Birdsey, and et al. Selective class I histone deacetylase inhibition suppresses hypoxia-induced cardiopulmonary remodeling through an antiproliferative mechanism Circ. Res. 110 2012 739 748
12. J. Kim, C. Hwangbo, X. Hu, Y. Kang, I. Papangeli, D. Mehrotra, and et al. Restoration of impaired endothelial myocyte enhancer factor 2 function rescues pulmonary arterial hypertension Circulation 131 2015 190 199
13. L. Zhao, C.N. Chen, N. Hajji, E. Oliver, E. Cotroneo, J. Wharton, and et al. Response to letter regarding article, "histone deacetylation inhibition in pulmonary hypertension: therapeutic potential of valproic acid and suberoylanilide hydroxamic acid" Circulation 127 2013 e540